BANGKOK, 28 September 2017 (NNT)
The Board of Investment of Thailand (BOI) has pledged to support investment in biopharmaceuticals and joined hands with Mahidol University to transfer manufacturing knowledge and technology.
Deputy BOI Secretary-General Duangjai Asawachintachit said the BOI had agreed to support Abinis Company Limited, a Thai biopharmaceuticals firm which is seeking to manufacture monoclonal antibody from animal cells to treat certain types of cancer and lupus.
The manufacturing of monoclonal antibody has never been performed in Thailand while the new type of biopharmaceutical for cancer and lupus treatment is considered a new invention which may only affect targeted cells while minimizing the effect on other healthy parts of the body, he said.
The project includes research and development on a new biopharmaceutical material for lupus treatment which allows the patients to inject the medicine by themselves without visiting hospitals.
The BOI had concluded that the project will be a breakthrough in Thailand's pharmaceutical industry, improving access to biopharmaceutical materials among patients, upgrading the manufacturing technology, and improving the country's competitiveness by cutting down the import and boosting the export of biopharmaceuticals in the future.
Abinis Company Limited is a firm partially owned by Siam Bioscience in cooperation with CIMAB S.A. under the supervision of the Cuban government.
Source: National News Bureau of Thailand
Illustration Photo: Thai Researcher, an ASEAN-U.S. Science & Technology Fellow (credits: Montakan Tanchaisawat, USAID / Flickr Creative Commons Attribution-NonCommercial 2.0 Generic (CC BY-NC 2.0))